Introduction
Protein 4.1 is a structural protein of 78-80 kD localized to the erythroid membrane skeleton that underlies the red cell plasma membrane. Protein 4.1 plays a critical role in regulating the mechanical properties of the erythrocyte membrane through multiple interactions with integral membrane proteins (band 3 and glycophorin C), with a membrane skeletal protein (spectrin), and with a cytoskeletal protein (actin). Genetic and biochemical evidence (1) (2) (3) clearly implicate mutations in protein 4 .1 in the etiology of some cases of hereditary elliptocytosis (HE), I which vary from mild to severe hemolytic anemia. Chromosome mapping studies have localized the human protein 4.1 gene to a site near the Rh locus that has been closely linked to HE (lp32 -) pter, references [3] [4] [5] . In addition, quantitative deficiencies (1, 2) or qualitative defects (4) in protein 4.1 have been found to co-segregate with the HE phenotype in at least four families, and restriction fragment length polymorphisms were linked to HE and partial 4.1 deficiency in another family (6) . In this report and the preceding companion paper (7), two novel structural variants of protein 4.1 are characterized. Both polypeptides are distinguished by aberrant electrophoretic mobilities on SDS-polyacrylamide gels, i.e., different from the normal apparent molecular weight of 78-80 kD (protein 4. l80). Based on biochemical analysis in the preceding paper, both also have structural alterations in the functionally important spectrin-actin binding domain. One is a low molecular weight variant (protein 4 .168/65) that in heterozygotes causes elliptocytosis and moderately severe hemolysis. Chemical and enzymatic cleavage patterns, as well as immunologic data, revealed a deletion of part or all of the spectrin-acting binding domain in protein 4 (10) . In the preceding paper (7) , biochemical analysis of these domains in the elongated variant protein 4.19 revealed an insertion in the 10-kD spectrin-acting binding domain between Lys406 and Lysg7, which are the first two residues of this domain, and a known exon boundary. Partial amino acid sequence data suggested that the insert represents an internal duplication of at least 57 amino acids from Arg473-Gln529 in the 24 kD domain (7) (Fig. 1 A) . In order to characterize further this unusual structural variant, 4.19S mRNA sequences were cloned and analyzed using 4.1-specific oligonucleotides (Table I) and PCR methodologies. Fig. 1 Protein 4.195 mRNA sequences encompassing the entire 15-kD insert were cloned next using a 5' oligonucleotide located upstream in the 16 kD domain and a 3' oligonucleotide precisely positioned at the 24-kD/ 10-kD junction at the 3' end of the insert. Since the 3' primer is derived from sequences in 24 kD and 10 kD that are discontinuous in 4.18°mRNA, no product was obtained when normal reticulocyte mRNA was amplified (reaction Ila). However, a DNA band of 587 bp was obtained from 4.19" mRNA (reaction Ilb). Sequence analysis of this DNA revealed normal coding sequences in the 16-kD region up to residue Lys4e7 at the start of 10 kD, followed by an insert of 123 amino acids representing a duplication of an almost intact 10-kD region (Lys407-Trp472) plus residues Arg473-Gln529 of 24 kD predicted from the protein studies.
The region of 4.195 mRNA 3' to the insert was cloned using oligonucleotide primers depicted in reaction ITl. Since the 5' oligonucleotide is present within the duplicated portion of 24 kD and the 3' primer is located in a downstream nonduplicated portionof 24 kD, two amplification products are possible using the 4.195 mRNA template (reaction IIIb). Upon sequencing, the larger 502 bp band revealed the COOH-terminal end of the insert (i.e., the 24-kD/10-kD junction), followed by a normal 10-kD and 24-kD sequence. Normal 4.1°mRNA possesses only one copy of the 5' primer and thus yields only a single 1 33-bp band (reaction IIa). Finally, amplification of sequences encoding the 30-and 16-kD domains, as well as the COOH-terminal end of 24 kD and parts of the 5' and 3' untranslated sequence, was accomplished using additional oligonucleotides (reactions IV-VII). All of these regions yielded PCR products that were indistinguishable in size from those obtained with normal 4.180 mRNA substrates (compare lanes a and b in Fig. 1 C) (7) , is shown in Fig. 2 (Fig. 2 C, arrowhead) (Fig. 3 B) . Similarly, the 80-aa deletion in protein 4.168/65 is due to deletion from the mRNA of only the first two of these exons (21 and 59 aa; Fig. 3 4.195 might be in an advantageous situation in which to evolve new binding interactions or new mechanisms to regulate existing interactions, since alterations in one domain would still leave one functional domain intact. Gene duplication and divergence events are known to play a major role in evolution; many genes, including even the erythroid membrane skeletal proteins spectrin (21) and ankyrin (22) , contain imperfect repeats indicative of past duplication events.
The putative duplication in the 4.195 gene has ramifications with respect to splicing of the resulting pre-mRNA. The 2 l-aa exon is known to be differentially spliced in a tissue-specific pattern such that it is expressed in erythroid cells but not in lymphocytes ( 13, 12) . The availability of both reticulocyte and lymphocyte 4.195 mRNA made it possible to ask whether this differential expression is maintained for both copies ofthis exon, since the 3' copy is flanked by a different upstream exon than is usual. By PCR amplification of this region of the mRNA it was determined that the 5' and 3' copies ofthe 2 l-aa exon behave similarly: both are spliced into the predominant erythroid 4.1 mRNA isoforms and out ofthe most abundant lymphoid isoforms. This finding implies that the signals for alternative mRNA processing of the 21-aa exon must be a function of the sequence in or near this exon itself, independent of the neighboring exon(s).
